Molecule Name |
DB09093
|
DrugBank Groups |
Approved
|
Cluster No |
113
|
Smiles |
ClC4(=C1(C(C(=O)C2(=C(O)C3(O)(C(=O)C(C(O)=N)=C(C(C3(CC2(C1(O)C)))N(C)C)O)))=C(O)C=C4))
|
Download |
mol2, pdbqt
|
TPSA |
182,61
|
Non-H Atoms |
33
|
Non-C/H Atoms |
11
|
Metal-Atoms |
0
|
Electronegative Atoms |
11
|
Stereo Centers |
5
|
Rotatable Bonds |
2
|
Rings Closures |
4
|
Small Rings |
4
|
Aromatic Rings |
1
|
Aromatic Atoms |
6
|
sp3-Atoms |
16
|
Symmetric atoms |
1
|
cLogS |
-1,669
|
MW |
478,884
|
cLogP |
-0,727
|
HBA |
10
|
HBD |
7
|
Ro5 violations |
1
|
Druglikeness |
4,4765
|
DrugScore |
0,762457840944869
|
Mutagenic |
none
|
Tumorigenic |
none
|
Reproductive Effective |
none
|
Irritant |
none
|
Blood-Brain Barrier |
BBB-
|
Human Intestinal Absorption |
HIA-
|
Caco-2 Permeability |
Caco2+
|
P-glycoprotein Substrate |
Substrate
|
P-glycoprotein Inhibitor |
Non-inhibitor
|
P-glycoprotein Inhibitor 2 |
Non-inhibitor
|
Renal Organic Cation Transporter |
Non-inhibitor
|
Aqueous solubility |
-2,8746
|
Caco-2 Permeability 2 |
0,5237
|
Subcellular localization |
Mitochondria
|
CYP450 2C9 Substrate |
Non-substrate
|
CYP450 2D6 Substrate |
Non-substrate
|
CYP450 3A4 Substrate |
Substrate
|
CYP450 1A2 Inhibitor |
Non-inhibitor
|
CYP450 2C9 Inhibitor |
Non-inhibitor
|
CYP450 2D6 Inhibitor |
Non-inhibitor
|
CYP450 2C19 Inhibitor |
Non-inhibitor
|
CYP450 3A4 Inhibitor |
Non-inhibitor
|
CYP Inhibitory Promiscuity |
Low CYP Inhibitory Promiscuity
|
Human Ether-a-go-go-Related Gene Inhibition |
Weak inhibitor
|
Human Ether-a-go-go-Related Gene Inhibition 2 |
Non-inhibitor
|
AMES Toxicity |
Non AMES toxic
|
Carcinogens |
Non-carcinogens
|
Fish Toxicity |
High FHMT
|
Fish Toxicity (pLC50, mg/L) |
0,8019
|
Tetrahymena Pyriformis Toxicity |
High TPT
|
Tetrahymena Pyriformis Toxicity (pIGC50, ug/L) |
0,7758
|
Honey Bee Toxicity |
Low HBT
|
Biodegradation |
Not ready biodegradable
|
Acute Oral Toxicity |
III
|
Rat Acute Toxicity (LD50, mol/kg) |
2,3561
|
Carcinogenicity (Three-class) |
Non-required
|